Forbion, a Naarden, The Netherlands and Munich, Germany-based life sciences venture capital firm, raised €1.35 billion ($1.5 billion) for its two newest funds.
The final close of the Forbion Ventures Fund VI, focused on building companies at an earlier stage of development, has reached the amount of €750m. The final close of the Forbion Growth Opportunities Fund II, which supports the expansion of late-stage life sciences companies, has also been secured at the amount of €600m.
The Forbion Ventures Fund VI will build a portfolio of highly impactful therapeutics companies including existing biotechs and new companies (co-) founded by Forbion, created around assets sourced from pharma or academic institutions, or around proven management teams. Forbion Ventures Fund VI saw a strong re-up rate by existing investors, and at the same time has attracted several new investors including Dutch pension funds PME and PMT, Loyola University of Chicago, the Scott Trust Endowment Ltd and Pictet Alternative Advisors.
The Forbion Growth Opportunities Fund II is focused on investing primarily in European later-stage biopharma companies developing novel therapies in areas of high medical need. In these financings, the team aims to take leading positions with investment sizes of up to €70m per deal. The fund has attracted several new institutional investors, including Amundi and Legal & General Capital which join Dutch pension funds PME and PMT, Pantheon and Eli Lilly and Company. Fund II has already made four investments to date.
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. The team invests in life sciences companies that are active in the (bio-) pharmaceutical space. Its current team consists of over 30 life sciences investment professionals that have built a performance track record since the late nineties with investments in 95 companies across 8 funds. Portfolio company successes include NewAmsterdam Pharma (NASDAQ: NAMS), Gyroscope (acquired by Novartis) and Replimune (NASDAQ: REPL).
This raise brought the total of funds under management at Forbion to €3 billion.
FinSMEs
20/04/2023